Skip to main content
Clinical Trials/NCT03641898
NCT03641898
Recruiting
Not Applicable

Intravascular Ultrasound-derived Morphometric Assessment of Fractional Flow Reserve Negative Lesions to Predict Cardiovascular Outcomes in Non-ST-segment Acute Coronary Syndrome Patients

Tianjin Chest Hospital1 site in 1 country350 target enrollmentOctober 20, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-ST-segment Acute Coronary Syndrome
Sponsor
Tianjin Chest Hospital
Enrollment
350
Locations
1
Primary Endpoint
The incidence and predictors of MACEs related to FNLs
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

This is an observational and prospective cohort study to examine whether the addition of IVUS plaque morphological evaluation to FFR haemodynamic assessment of non-culprit lesions in NSTEACS patients will better predict MACEs.

Detailed Description

IMPACT-NSTEACS is a prospective, single-centre and dynamic observational study. The study population consists of NSTEACS patients who undergo FFR in lesions with intermediate to severe angiographic stenosis. Then, FFR-guided PCI is performed, followed by morphological assessment based on IVUS in all FFR-negative lesions (FNLs). After discharge all patients receive optimal medication treatment and are followed up clinically. On the basis of follow-up angiography, MACEs are further adjudicated as occurring at FNLs or not.

Registry
clinicaltrials.gov
Start Date
October 20, 2018
End Date
October 2025
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ying Zhang

Senior Physician

Tianjin Chest Hospital

Eligibility Criteria

Inclusion Criteria

  • Moderate to high risk NSTEACS requiring invasive strategy based on current guidelines and local clinical practice.
  • Patient agrees and is able to follow all protocol procedures.

Exclusion Criteria

  • STEMI or SCAD.
  • Hemodynamic instability (e.g. cardiogenic shock, refractory ventricular arrhythmias, acute and severe conduction system disease and left ventricular ejection fraction ≤30%).
  • Contraindication for FFR, PCI, IVUS and OMT (e.g. severe allergy to antiplatelet drug or contrast, significant bleed within the past 6 months, bleeding diathesis and serum creatinine ≥2.5 mg/dl).
  • PCI within 6 months or any prior CABG.
  • Anticipated life expectancy \<3 year.
  • Unwilling or unable to provide informed consent
  • Imaging Inclusion Criteria
  • Patients must have at least \> 1 de novo lesion in a native coronary segment with a visually estimated diameter stenosis of between 40 and 90 %.
  • Successful FFR-guided PCI performed in all major epicardial coronary arteries (including their branches): PCI for all lesions a) with 40%-90% diameter stenosis and FFR\<0.8 and b) with ≥90% diameter stenosis.
  • The FFR-negative lesions must be available for assessment of IVUS.

Outcomes

Primary Outcomes

The incidence and predictors of MACEs related to FNLs

Time Frame: 3 years

Composite of death from cardiac causes, myocardial infarction, rehospitalization due to unstable or progressive angina and clinically-driven target lesion revascularization

Secondary Outcomes

  • The incidence of MACEs related to PCI-treated lesions(3 years)

Study Sites (1)

Loading locations...

Similar Trials